[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tick-borne-encephalitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tick-borne-encephalitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638089","phase-3-dexamethasone-in-tick-borne-encephalitis-100638089",false,"NCT07584525","Dexamethasone in Tick-borne Encephalitis","Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical Trial","Inclusion Criteria:\n\n* age 18 years or older and\n* clinical signs and symptoms of meningoencephalitis or meningomyelitis and\n* cerebrospinal pleocytosis and\n* serological confirfmation of tick-borne encephalitis virus infection\n\nExclusion Criteria:\n\n* pregnancy or\n* severe neurological impairment befor tick-borne encephalitis or\n* systemic corticosteroid treatment in the past 30 days or\n* allergy to corticosteroids or\n* immunosuppresive condition or therapy such as HIV with CD4 \\\u003C 200\u002Fml, organ or bone marrow transplant, receiving chemotherapy, radiotherapy or any other immunosuppresive therapy, primary immunodeficiency, hematological maliganncy or\n* ventricular shunt or\n* endoscopically documented peptic gastric ulcer in the past six months or gastrointestinal bleeding with hemoglobin drop ≥ 20 units or\n* uncontrolled diabetes with hyperglicemia or\n* antiviral therapy with rilpivirin",true,"ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to investigate the efficacy of dexamethasone in patients with tick-borne encephalitis.",[27],"Tick-Borne Encephalitis","RECRUITING","2026-05-07",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":32},"2024-05-03",{"date":36,"type":21},"2030-09-30",{"name":38,"class":39},"University Medical Centre Ljubljana","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100359159","tick-borne-encephalitis-and-borrelial-antibodies-in-serum-100359159","NCT03956446","Tick-borne Encephalitis and Borrelial Antibodies in Serum","Antibiotic Therapy for Patients With Tick-borne Encephalitis and Borrelial Antibodies in Serum","Inclusion Criteria:\n\n* 18 years or older\n* clinical picture compatible with tick-borne encephalitis,\n* clear cerebrospinal fluid,\n* cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid \\>5 x 106\u002F)L,\n* positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against tick-borne encephalitis virus,\n* positive serum IgG antibodies against Lyme borreliae.\n\nExclusion Criteria:\n\n* isolation of B.burgdorferi sensu lato from cerebrospinal fluid,\n* positive intrathecal borrelial antibody production index,\n* seroconversion of borrelial IgG antibodies,\n* presence of erythema migrans and\u002For borrelial lymphocytoma in the last month,\n* Bannwarth syndrome.",{"count":49,"type":21},80,[51],"NA","In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick. In clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne encephalitis antibodies in serum of a patient with compatible clinical presentation and cerebrospinal pleocytosis. Patients with Lyme meningitis or meningoradiculitis also have cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not attest Lyme neuroborreliosis. Patients with tick-borne encephalitis and positive borrelial antibodies in serum, but not fulfilling criteria for Lyme neuroborreliosis, are often being treated with antibiotics in several European countries due to the possibility of double infection. The investigators hypothesise that such patients do not benefit from antibiotics. Such an approach may appear safe regarding the possibility of borrelial infection, however it can also be associated with detrimental consequences such as antibiotic related adverse reactions, negative epidemiological impact on bacterial resistance, and intravenous catheter related complications.",[54],"Tick Borne Encephalitis","2025-03-24",{"date":57,"type":32},"2025-03-25",{"date":59,"type":32},"2014-09-01",{"date":61,"type":21},"2027-12-31",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":94,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.",{"count":72,"type":21},183,[51],"Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93],"Leishmaniasis","Leptospirosis","Brucellosis","Q Fever","Rickettsiosis","Tularemia","Psittacosis","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Hepatitis E","Dengue Virus","Zika Virus","Chikungunya Virus Infection","West Nile Virus","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[95,77,78,96,97,98,99,100,101,102,103,104,105,106,81,82,107,108],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","NOT_YET_RECRUITING","2025-02-27",{"date":112,"type":32},"2025-03-05",{"date":114,"type":21},"2025-03-03",{"date":116,"type":21},"2025-10-03",{"name":118,"class":39},"University Hospital, Montpellier"]